Celularity Inc. Research and Development Expense
Celularity Inc. (CELU) reported Research and Development Expense of $15.03 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-04-30
- Celularity Inc. research and development expense for the quarter ending 2025-12-31 was $3.35M, a 12.57% decline year-over-year.
- Celularity Inc. research and development expense for the quarter ending 2025-09-30 was $4.60M, a 17.45% increase year-over-year.
- Celularity Inc. research and development expense for the quarter ending 2025-06-30 was $3.35M, a 11.79% decline year-over-year.
- Celularity Inc. research and development expense for the quarter ending 2025-03-31 was $3.73M, a 36.20% decline year-over-year.
- Celularity Inc. research and development expense for fiscal 2025 was $15.03M, a 13.58% decline from fiscal 2024.
- Celularity Inc. research and development expense for fiscal 2024 was $17.39M, a 42.93% decline from fiscal 2023.
- Celularity Inc. research and development expense for fiscal 2023 was $30.46M, a 61.12% decline from fiscal 2022.
- Celularity Inc. research and development expense for fiscal 2022 was $78.36M, a 11.31% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $7.95M derived: sum of 2 quarters · filed 2026-04-30 | $11.30M derived: sum of 3 quarters · filed 2026-04-30 | $15.03M 10-K · filed 2026-04-30 |
| 2025-09-30 | $4.60M 10-Q · filed 2025-11-14 | $7.95M derived: sum of 2 quarters · filed 2025-11-14 | $11.68M 10-Q · filed 2025-11-14 | $15.51M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-06-30 | $3.35M 10-Q · filed 2025-08-29 | $7.08M 10-Q · filed 2025-08-29 | $10.91M derived: sum of 3 quarters · filed 2026-04-30 | $14.82M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-03-31 | $3.73M 10-Q · filed 2025-08-29 | $7.56M derived: sum of 2 quarters · filed 2026-04-30 | $11.47M derived: sum of 3 quarters · filed 2026-04-30 | $15.27M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $7.74M derived: sum of 2 quarters · filed 2026-04-30 | $11.54M derived: sum of 3 quarters · filed 2026-04-30 | $17.39M 10-K · filed 2026-04-30 |
| 2024-09-30 | $3.92M 10-Q · filed 2025-11-14 | $7.71M derived: sum of 2 quarters · filed 2025-11-14 | $13.56M 10-Q · filed 2025-11-14 | $13.29M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $3.80M 10-Q · filed 2025-08-29 | $9.64M 10-Q · filed 2025-08-29 | $9.37M derived: sum of 3 quarters · filed 2025-08-29 | $14.55M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | $5.84M 10-Q · filed 2025-08-29 | $5.57M derived: sum of 2 quarters · filed 2025-08-29 | $10.75M derived: sum of 3 quarters · filed 2025-08-29 | $19.36M derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | -$272.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $4.91M derived: sum of 2 quarters · filed 2025-05-08 | $13.51M derived: sum of 3 quarters · filed 2025-05-08 | $30.46M 10-K · filed 2025-05-08 |
| 2023-09-30 | $5.18M 10-Q · filed 2024-12-06 | $13.79M derived: sum of 2 quarters · filed 2024-12-06 | $30.74M 10-Q · filed 2024-12-06 | $41.73M derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | $8.60M 10-Q · filed 2024-11-07 | $25.55M 10-Q · filed 2024-11-07 | $36.55M derived: sum of 3 quarters · filed 2024-11-07 | $56.90M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $16.95M 10-Q · filed 2024-10-16 | $27.94M derived: sum of 2 quarters · filed 2024-10-16 | $48.29M derived: sum of 3 quarters · filed 2024-10-16 | $73.64M derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | $10.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $31.34M derived: sum of 2 quarters · filed 2024-07-30 | $56.69M derived: sum of 3 quarters · filed 2024-07-30 | $78.36M 10-K · filed 2024-07-30 |
| 2022-09-30 | $20.35M 10-Q · filed 2024-01-03 | $45.70M derived: sum of 2 quarters · filed 2024-01-03 | $67.37M 10-Q · filed 2024-01-03 | $92.06M derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | $25.35M 10-Q · filed 2023-08-14 | $47.02M 10-Q · filed 2023-08-14 | $71.71M derived: sum of 3 quarters · filed 2023-08-14 | $95.47M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $21.67M 10-Q · filed 2023-05-22 | $46.36M derived: sum of 2 quarters · filed 2023-05-22 | $70.13M derived: sum of 3 quarters · filed 2023-05-22 | $93.04M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $24.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $48.45M derived: sum of 2 quarters · filed 2023-03-31 | $71.36M derived: sum of 3 quarters · filed 2023-03-31 | $88.35M 10-K · filed 2023-03-31 |
| 2021-09-30 | $23.77M 10-Q · filed 2022-11-10 | $46.68M derived: sum of 2 quarters · filed 2022-11-10 | $63.67M 10-Q · filed 2022-11-10 | $77.59M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $22.91M 10-Q · filed 2022-08-09 | $39.90M 10-Q · filed 2022-08-09 | $53.83M derived: sum of 3 quarters · filed 2022-08-09 | $65.04M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $16.99M 10-Q · filed 2022-05-16 | $30.91M derived: sum of 2 quarters · filed 2022-05-16 | $42.13M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $13.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $25.14M derived: sum of 2 quarters · filed 2022-03-31 | $52.71M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $11.22M 10-Q · filed 2021-11-12 | $38.78M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |